2024-06-13 10:51:28 ET
This firm develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. And news of a potential licensing agreement is sending shares soaring in morning trade.
With two core clinical development programs related to the treatment of disc/spine disease and metabolic disorders, and a recent offering in bio-cosmeceutical products, %BioRestorativeTherapies Inc. (NASDAQ: ) is a clinical-stage company focused on stem cell-based therapies. The firm reported in a press release today that it has had substantive discussions with an undisclosed commercial-stage regenerative medicine company with regard to a license of BioRestorative’s allogeneic, off-the-shelf ThermoStem ® metabolic intellectual property.
In a previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine demonstrated a clonogenic population of metabolically active brown adipose tissue (“BAT”) stem cells residing in adult humans that: (i) can be expanded in vitro ; (ii) exhibit multilineage differentiation potential (osteogenetic, chondrogenic and adipogenic); and (iii), functionally differentiate into metabolically active brown adipocytes. In addition, the preclinical results confirmed that multipotent brown adipose derived stem cells (“BADSCs”) induced to differentiate into brown adipocytes exhibit the mature functional properties of these cells, including increased mitochondrial activity, an important functional characteristic of BAT. The company feels this would represent an exciting new modality for the treatment of obesity and related metabolic disorders.
While no assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise, shares were up over 36 percent in heavy trading.